標(biāo)題: Titlebook: Breast Cancer; A Guide to Clinical Adnan Aydiner,Abdullah Igci,Atilla Soran Book 2019 Springer Nature Switzerland AG 2019 breast disease.c [打印本頁] 作者: foresight 時(shí)間: 2025-3-21 19:13
書目名稱Breast Cancer影響因子(影響力)
書目名稱Breast Cancer影響因子(影響力)學(xué)科排名
書目名稱Breast Cancer網(wǎng)絡(luò)公開度
書目名稱Breast Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Breast Cancer被引頻次
書目名稱Breast Cancer被引頻次學(xué)科排名
書目名稱Breast Cancer年度引用
書目名稱Breast Cancer年度引用學(xué)科排名
書目名稱Breast Cancer讀者反饋
書目名稱Breast Cancer讀者反饋學(xué)科排名
作者: 象形文字 時(shí)間: 2025-3-21 20:46
Eva Below,Wolfram Ebinger,Ulrich Pramannreast as a primary lesion, including liposarcoma, leiomyosarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, and osteosarcoma. Fibroepithelial tumors are biphasic neoplasms characterized by the proliferation of both epithelial and mesenchymal elements. Fibroadenoma and phyllodes tumors constitute the major entities.作者: Homocystinuria 時(shí)間: 2025-3-22 01:59 作者: 鎮(zhèn)痛劑 時(shí)間: 2025-3-22 07:51 作者: exorbitant 時(shí)間: 2025-3-22 12:23
Nuclear Medicine Imaging in Breast Canceraging with PET is a rapidly emerging approach in breast cancer, conventional single-photon nuclear medicine imaging, including bone scintigraphy and sentinel lymph node scintigraphy, still has an important role in the management of breast cancer. This chapter outlines the role of nuclear medicine imaging in patients with breast cancer.作者: 小爭吵 時(shí)間: 2025-3-22 16:42 作者: indecipherable 時(shí)間: 2025-3-22 17:24
In Situ Cancer Treatmentof invasive breast cancer. This chapter focuses on recommendations for workup, primary treatment, risk reduction strategies, and surveillance specific to carcinoma in situ, which represents approximately 20% of all breast cancers diagnosed by mammography.作者: FRET 時(shí)間: 2025-3-22 22:52 作者: 被告 時(shí)間: 2025-3-23 02:23
Intraoperative Pathological Examination of Breast Lesionsmethod is typically either frozen section (FS) or cytology in addition to gross examination, although some molecular techniques have recently been developed for intraoperative pathological examination (IPE).作者: Guaff豪情痛飲 時(shí)間: 2025-3-23 07:41
Prognostic and Predictive Factorshese assays are based on the identification of prognostic gene signatures by using microarrays. Many groups have attempted to develop genomic tests based on genomic profiling to improve the prediction of clinical outcome compared with standard pathological and clinical markers.作者: hankering 時(shí)間: 2025-3-23 12:41 作者: 浪蕩子 時(shí)間: 2025-3-23 16:36 作者: 下船 時(shí)間: 2025-3-23 19:36 作者: BOON 時(shí)間: 2025-3-24 00:19 作者: 出汗 時(shí)間: 2025-3-24 05:36 作者: 摘要 時(shí)間: 2025-3-24 07:59
Gerhard Schmitt-Rink,Dieter Bender triple-negative breast cancers. The decision regarding neoadjuvant treatment should be made after a discussion of the patient’s clinical, histological, and imaging characteristics by a multidisciplinary oncology board that includes surgical oncologists, medical oncologists, radiation oncologists, radiologists, and pathologists.作者: 充滿裝飾 時(shí)間: 2025-3-24 14:31
Book 2019st cancer. It also includes the definitions of statistical terminologies and their usage in clinical practice and research. This is a comprehensive yet concise resource for residents, fellows, and early-career practitioners.?.作者: 比目魚 時(shí)間: 2025-3-24 18:31
Volkseinkommen, L?hne und Gewinneostic stage tables. The pathological stage table is based on clinical information, biomarker data, and findings from surgery and resected tissue. It is anticipated that updates will be made on a more frequent basis than the 6- to 8-year?cycle of TNM revisions, when relevant validated information is available.作者: hemoglobin 時(shí)間: 2025-3-24 21:54 作者: 金絲雀 時(shí)間: 2025-3-24 23:28 作者: Palpitation 時(shí)間: 2025-3-25 06:51 作者: 表示問 時(shí)間: 2025-3-25 09:51 作者: Pathogen 時(shí)間: 2025-3-25 14:21
Evaluation of Axillary Nodesreat pathologic response rates, the axilla can become negative in up to 60% of cases, depending on tumor biology. In these cases, SLNB can be performed with low false-negative rates, and the axilla can be saved as in early breast cancer.作者: 半導(dǎo)體 時(shí)間: 2025-3-25 19:32 作者: Orchiectomy 時(shí)間: 2025-3-25 23:49
http://image.papertrans.cn/b/image/190543.jpg作者: enchant 時(shí)間: 2025-3-26 03:54 作者: 勾引 時(shí)間: 2025-3-26 07:28
Volkseinkommen, L?hne und Gewinnessess the prognosis of patients with newly diagnosed breast cancer. In 2009, the seventh revised edition of the TNM system was published to reflect the updates in technology and clinical evidence. Rapid advances in both clinical and laboratory sciences along with translational research have raised q作者: Ibd810 時(shí)間: 2025-3-26 11:50
Makro?konomisches Gleichgewichtast. Ductal carcinoma in situ (DCIS) is characterized by the neoplastic proliferation of epithelial cells confined to the ductal-lobular system of the breast without evidence of invasion through the basement membrane into the surrounding stroma. Most cases of DCIS are positive for estrogen receptor 作者: 公共汽車 時(shí)間: 2025-3-26 16:36
Eva Below,Wolfram Ebinger,Ulrich Pramannnd schwannoma. Malignant mesenchymal tumors of the breast other than angiosarcomas are extremely rare. However, any type of sarcoma may occur in the breast as a primary lesion, including liposarcoma, leiomyosarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, and osteosarcoma. Fibroep作者: 壟斷 時(shí)間: 2025-3-26 18:08 作者: 漸變 時(shí)間: 2025-3-27 00:53
,Nachfrage, Einkommen und Verm?gen,e tumor size, axillary lymph node status, histological features, hormone receptor status, HER2 status and the proliferative capacity of the tumor. Several gene expression profiling assays have been developed in an attempt to predict the survival and response to therapies of breast cancer patients. T作者: Intend 時(shí)間: 2025-3-27 03:50
,Vollbesch?ftigung und Inflation,ment. Mammography is an essential and widely used imaging modality for breast cancer screening, and it has led to a reduced mortality rate. Ultrasonography (US) examination and magnetic resonance imaging (MRI) are also offered as diagnostic techniques and as adjuncts for pre and postoperative workup作者: 一個(gè)攪動(dòng)不安 時(shí)間: 2025-3-27 07:10
https://doi.org/10.1007/978-3-642-58441-1velopments in breast imaging have been achieved include a diversity of breast imaging modalities, including whole-body PET systems. While molecular imaging with PET is a rapidly emerging approach in breast cancer, conventional single-photon nuclear medicine imaging, including bone scintigraphy and s作者: Esophagus 時(shí)間: 2025-3-27 11:16
https://doi.org/10.1007/978-3-322-94602-7ients with breast cancer. PSC has evolved into an integral part of the multidisciplinary treatment approach for breast cancer and has a long history that spans nearly four decades. Despite previous beliefs that it is more suitable for locally advanced or inflammatory disease, PSC is increasingly pop作者: 上下連貫 時(shí)間: 2025-3-27 16:59
Gerhard Schmitt-Rink,Dieter Benderbreast cancer. Preoperative systemic therapy should be an option for patients who would require adjuvant systemic therapy. Neoadjuvant therapy is most appropriate for patients likely to have a good locoregional response, regardless of tumor size at presentation, including those with HER2-positive or作者: PIZZA 時(shí)間: 2025-3-27 20:45
Gerhard Schmitt-Rink,Dieter Benderythema, edema, and peau d’orange over a third or more of the skin of the breast due to the occlusion of dermal mammary lymphatics by tumor emboli. IBC is associated with rapid progression, with a high risk of axillary lymph node involvement and distant metastases at initial diagnosis. The treatment 作者: Sinus-Node 時(shí)間: 2025-3-27 23:36 作者: 血友病 時(shí)間: 2025-3-28 02:31
Gerhard Schmitt-Rink,Dieter Benderr the last several decades. With the arrival of sentinel lymph node biopsy, surgical practice for axillary staging in patients with early stage breast cancer has gradually become less invasive, and formal axillary lymph node dissection has been confined to selected patients. Over the last two decade作者: Interferons 時(shí)間: 2025-3-28 08:24 作者: LASH 時(shí)間: 2025-3-28 14:03 作者: 感情脆弱 時(shí)間: 2025-3-28 14:58
978-3-030-07277-3Springer Nature Switzerland AG 2019作者: 項(xiàng)目 時(shí)間: 2025-3-28 19:34
Decision Pathways in Breast Cancer Managementeast cancer, the treatment strategy is chosen based on the features and biology of the tumor and on the patient’s age, general health status and personal preferences. The decision options are based on the best evidence-based recommendations. The decision process is based on comprehensive guidelines 作者: Genetics 時(shí)間: 2025-3-29 01:26
Breast Cancer Stagingssess the prognosis of patients with newly diagnosed breast cancer. In 2009, the seventh revised edition of the TNM system was published to reflect the updates in technology and clinical evidence. Rapid advances in both clinical and laboratory sciences along with translational research have raised q作者: 頭盔 時(shí)間: 2025-3-29 05:27
Pathology of Breast Cancerast. Ductal carcinoma in situ (DCIS) is characterized by the neoplastic proliferation of epithelial cells confined to the ductal-lobular system of the breast without evidence of invasion through the basement membrane into the surrounding stroma. Most cases of DCIS are positive for estrogen receptor 作者: Microaneurysm 時(shí)間: 2025-3-29 07:29
Mesenchymal and Fibroepithelial Tumors of the Breastnd schwannoma. Malignant mesenchymal tumors of the breast other than angiosarcomas are extremely rare. However, any type of sarcoma may occur in the breast as a primary lesion, including liposarcoma, leiomyosarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, and osteosarcoma. Fibroep作者: 破裂 時(shí)間: 2025-3-29 11:27 作者: ITCH 時(shí)間: 2025-3-29 16:14 作者: breadth 時(shí)間: 2025-3-29 23:32 作者: aviator 時(shí)間: 2025-3-30 02:03 作者: 表示向下 時(shí)間: 2025-3-30 04:38
Preoperative Systemic Therapy for Operable Breast Cancerients with breast cancer. PSC has evolved into an integral part of the multidisciplinary treatment approach for breast cancer and has a long history that spans nearly four decades. Despite previous beliefs that it is more suitable for locally advanced or inflammatory disease, PSC is increasingly pop作者: CAMEO 時(shí)間: 2025-3-30 11:03 作者: PIZZA 時(shí)間: 2025-3-30 14:29 作者: 昏睡中 時(shí)間: 2025-3-30 19:23
In Situ Cancer Treatments of pleomorphic LCIS are accepted as more complex lesions and are more likely to be associated with invasive carcinoma. Ductal carcinoma in situ (DCIS) is a heterogeneous group of diseases that differ in biology and clinical behavior. DCIS is the putative precursor of the majority of invasive breas作者: OGLE 時(shí)間: 2025-3-31 00:04 作者: 乞丐 時(shí)間: 2025-3-31 03:11
